Effects of pioglitazone on the incidence of dementia in patients with diabetes

Journal of Diabetes and its Complications

Volumn 31, Issue 6, 2017, Pages 1053-1057

  Chou, Ping Song ^a   Ho, Bo Lin ^a   Yang, Yuan Han ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Dementia; Diabetes mellitus; National health insurance research database; Peroxisome proliferator activated receptor gamma; Pioglitazone

Indexed keywords

PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ADULT; AGE; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SEX DIFFERENCE; SURVIVAL RATE; AGED; CASE CONTROL STUDY; DOSE RESPONSE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PSYCHOLOGY; RISK FACTOR; TAIWAN; TOXICITY AND INTOXICATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DEMENTIA; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; RISK FACTORS; TAIWAN; THIAZOLIDINEDIONES;

EID: 85013057058     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2017.01.006     Document Type: Article

References (32)

1. Ahtiluoto, S., Polvikoski, T., Peltonen, M., Solomon, A., Tuomilehto, J., Winblad, B., Kivipelto, M., Diabetes, Alzheimer disease, and vascular dementia: A population-based neuropathologic study. Neurology 75:13 (2010), 1195–1202, 10.1212/WNL.0b013e3181f4d7f8.
2. Beyer, A.M., Baumbach, G.L., Halabi, C.M., Modrick, M.L., Lynch, C.M., Gerhold, T.D., Faraci, F.M., Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension 51:4 (2008), 867–871, 10.1161/HYPERTENSIONAHA.107.103648.
3. Biessels, G.J., Staekenborg, S., Brunner, E., Brayne, C., Scheltens, P., Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurology 5:1 (2006), 64–74, 10.1016/S1474-4422(05)70284-2.
4. Carlsson, C.M., Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. Journal of Alzheimer's Disease 20:3 (2010), 711–722, 10.3233/JAD-2010-100012.
5. Cheng, P.Y., Sy, H.N., Wu, S.L., Wang, W.F., Chen, Y.Y., Newly diagnosed type 2 diabetes and risk of dementia: A population-based 7-year follow-up study in Taiwan. Journal of Diabetes and its Complications 26:5 (2012), 382–387, 10.1016/j.jdiacomp.2012.06.003.
6. Combs, C.K., Johnson, D.E., Karlo, J.C., Cannady, S.B., Landreth, G.E., Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. The Journal of Neuroscience 20:2 (2000), 558–567.
7. Craft, S., Insulin resistance and Alzheimer's disease pathogenesis: Potential mechanisms and implications for treatment. Current Alzheimer Research 4:2 (2007), 147–152.
8. Craft, S., The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Archives of Neurology 66:3 (2009), 300–305, 10.1001/archneurol.2009.27.
9. de la Monte, S.M., Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Current Alzheimer Research 9:1 (2012), 35–66.
10. Di Marco, L.Y., Venneri, A., Farkas, E., Evans, P.C., Marzo, A., Frangi, A.F., Vascular dysfunction in the pathogenesis of Alzheimer's disease—A review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiology of Disease 82 (2015), 593–606, 10.1016/j.nbd.2015.08.014.
11. Heneka, M.T., Fink, A., Doblhammer, G., Effect of pioglitazone medication on the incidence of dementia. Annals of Neurology 78:2 (2015), 284–294, 10.1002/ana.24439.
12. Heneka, M.T., Klockgether, T., Feinstein, D.L., Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. The Journal of Neuroscience 20:18 (2000), 6862–6867.
13. Heneka, M.T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., Landreth, G.E., Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128:Pt 6 (2005), 1442–1453, 10.1093/brain/awh452.
14. Hsu, C.C., Wahlqvist, M.L., Lee, M.S., Tsai, H.N., Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. Journal of Alzheimer's Disease 24:3 (2011), 485–493, 10.3233/JAD-2011-101524.
15. Imfeld, P., Bodmer, M., Jick, S.S., Meier, C.R., Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case–control study. Journal of the American Geriatrics Society 60:5 (2012), 916–921, 10.1111/j.1532-5415.2012.03916.x.
16. Luna-Medina, R., Cortes-Canteli, M., Alonso, M., Santos, A., Martinez, A., Perez-Castillo, A., Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. The Journal of Biological Chemistry 280:22 (2005), 21453–21462, 10.1074/jbc.M414390200.
17. Mittal, K., Katare, D.P., Shared links between type 2 diabetes mellitus and Alzheimer's disease: A review. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2016, 10.1016/j.dsx.2016.01.021.
18. Ng, T.P., Feng, L., Yap, K.B., Lee, T.S., Tan, C.H., Winblad, B., Long-term metformin usage and cognitive function among older adults with diabetes. Journal of Alzheimer's Disease 41:1 (2014), 61–68, 10.3233/JAD-131901.
19. Nicolakakis, N., Aboulkassim, T., Ongali, B., Lecrux, C., Fernandes, P., Rosa-Neto, P., Hamel, E., Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. The Journal of Neuroscience 28:37 (2008), 9287–9296, 10.1523/JNEUROSCI.3348-08.2008.
20. Pasceri, V., Wu, H.D., Willerson, J.T., Yeh, E.T., Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101:3 (2000), 235–238.
21. Peila, R., Rodriguez, B.L., Launer, L.J., Honolulu-Asia Aging Study, Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51:4 (2002), 1256–1262.
22. Perez, M.J., Quintanilla, R.A., Therapeutic actions of the thiazolidinediones in Alzheimer's disease. PPAR Research, 2015, 2015, 957248, 10.1155/2015/957248.
23. Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., Ferri, C.P., The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 9:1 (2013), 63–75.e2, 10.1016/j.jalz.2012.11.007.
24. Sastre, M., Dewachter, I., Landreth, G.E., Willson, T.M., Klockgether, T., van Leuven, F., Heneka, M.T., Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. The Journal of Neuroscience 23:30 (2003), 9796–9804.
25. Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., Heneka, M.T., Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proceedings of the National Academy of Sciences of the United States of America 103:2 (2006), 443–448, 10.1073/pnas.0503839103.
26. Sharma, B., Singh, N., Behavioral and biochemical investigations to explore pharmacological potential of PPAR-gamma agonists in vascular dementia of diabetic rats. Pharmacology, Biochemistry, and Behavior 100:2 (2011), 320–329, 10.1016/j.pbb.2011.08.020.
27. Tsuchiya, K., Akaza, I., Yoshimoto, T., Hirata, Y., Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes. Endocrine Journal 56:5 (2009), 691–698.
28. Verrier, E., Wang, L., Wadham, C., Albanese, N., Hahn, C., Gamble, J.R., Xia, P., PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: Role of diacylglycerol kinase. Circulation Research 94:11 (2004), 1515–1522, 10.1161/01.RES.0000130527.92537.06.
29. Watson, G.S., Craft, S., The role of insulin resistance in the pathogenesis of Alzheimer's disease: Implications for treatment. CNS Drugs 17:1 (2003), 27–45.
30. Willette, A.A., Johnson, S.C., Birdsill, A.C., Sager, M.A., Christian, B., Baker, L.D., Bendlin, B.B., Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement 11:5 (2015), 504–510.e1, 10.1016/j.jalz.2014.03.011.
31. Xu, W.L., Qiu, C.X., Wahlin, A., Winblad, B., Fratiglioni, L., Diabetes mellitus and risk of dementia in the Kungsholmen project: A 6-year follow-up study. Neurology 63:7 (2004), 1181–1186.
32. Yamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M.P., Heneka, M.T., PPARgamma/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. The Journal of Neuroscience 32:48 (2012), 17321–17331, 10.1523/JNEUROSCI.1569-12.2012.